Clinical Trial Update: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial [Phase 2]

View source ↗

Summary

A Phase 2 ComboMATCH trial evaluates the combination of palbociclib and binimetinib in RAS-mutant cancers, including pancreatic and ovarian cancers, sponsored b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Ovarian Serous Carcinoma
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING